> ## Content Index
> Fetch the complete content index at: https://www.melaninblissmedia.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# The Barbershop Trial Worked. Who Would Run It Next?
- URL: https://www.melaninblissmedia.com/the-barbershop-trial-worked-who-would-run-it-next/
- Published: 2026-11-17T12:01:41.000Z
- Updated: 2026-11-17T12:01:41.000Z
- Description: A randomized trial in Los Angeles barbershops cut blood pressure far more than usual care. This feature follows the back-office questions the result left open: who prescribes, who supervises, who pays, and who drives to the shop.
- Author: Amber McClendon
- Tags: Health, Public Health

Stories about barbers who check blood pressure are common in health coverage. This feature goes to a different place. It asks what the largest randomized trial of the barbershop idea actually required behind the scenes, what its authors and later researchers say it cannot show, and why a result of that size has not turned into a service a man can simply be referred to.

The trial is the Los Angeles Barbershop Blood Pressure Study, published in the New England Journal of Medicine in 2018.\[1\] It enrolled 319 Black male barbershop patrons with systolic blood pressure of 140 mm Hg or higher. At six months, systolic pressure had fallen by 27.0 mm Hg in the group that received pharmacist-led care and by 9.3 mm Hg in the comparison group, a difference of 21.6 mm Hg (95% confidence interval 14.7 to 28.4).\[1\] The numbers are striking. The interesting part for a reporter is how many separate jobs sat underneath them, and which of those jobs the trial supplied for free to the people in the chairs.

MB has no connection to these trials, and this piece reports only what the published papers say. It does not evaluate any barbershop, pharmacy or health system, and it describes no program that MB has visited.

| **AN ILLUSTRATIVE SCENARIO (NOT A REAL PERSON)** This is a composite built to organize questions. It is not someone MB interviewed, and it does not describe an actual shop. A man in his forties gets a haircut every two weeks. The barber, who has taken a short training, wraps a cuff on his arm and reads a number that is high. The barber says to see a doctor. The man does not have a doctor he sees regularly. He leaves with a card, a good haircut and a number he now knows. Everything that happens next requires a person to prescribe, a person to supervise the prescription, a person to check his kidneys after a medicine change, and a person to pay for all of it. The sections below ask who those people were in the trial, and who they could be afterward. |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |

## What the trial measured

The design matters because it explains what the result does and does not mean. Barbershops, not individual men, were randomized, in a 1:1 ratio. In the intervention shops, barbers were trained to encourage follow-up with specialty-trained pharmacists and to measure blood pressure. The pharmacists met men in the shops, prescribed medicine under a collaborative practice agreement with each man's doctor, and sent progress notes to that doctor. In the comparison shops, barbers encouraged lifestyle change and doctor appointments.\[1\]

The main finding was blood pressure at six months. The share of men reaching a level below 130/80 mm Hg was 63.6% in the intervention group and 11.7% in the comparison group. Retention was 95%. There were no treatment-related serious adverse events, and three men in the intervention group had transient acute kidney injury; in each case the regimen included indapamide, and the injury resolved when it was stopped.\[1\] Use of blood pressure medication rose from 55% to 100% in the intervention group and from 53% to 63% in the comparison group.\[1\]

A 12-month follow-up of the same cohort tested whether the effect lasted while pharmacist visits were reduced. At 12 months, systolic pressure was 20.8 mm Hg lower in the intervention group than in the comparison group (95% CI 13.9 to 27.7), and 68.0% of the intervention group versus 11.0% of the comparison group were below 130/80 mm Hg. Retention in both groups was 90%.\[2\]

The size of the difference is partly a story about the comparison. The authors note that the previous barbershop trial they ran produced a difference of only 2.5 mm Hg, in which barbers checked pressure and urged men to see a doctor, and that clinicians in busy primary care practices often do not intensify drug therapy.\[1\] A post hoc analysis of that earlier trial found that men whose barbers referred them to hypertension specialists had a systolic reduction 21 mm Hg greater than the comparison group, while men referred to ordinary primary care providers did not differ from it (4 mm Hg, p = 0.31).\[5\] The groups in that analysis were small, with 33 to 68 men each. It is a hint, not a proof, but it points the same direction as the 2018 trial: the barbershop opened the door, and the treatment on the other side of the door made the difference.

## What the numbers cannot show

The authors list their own limits. Assignment could not be blinded. The pharmacists aimed for an in-shop pressure below 130/80 mm Hg, while primary care providers treating the comparison group probably aimed for below 140/90, so the groups were chasing different targets. The comparison group may have included more men reluctant to take prescription drugs. Men in the intervention group were measured more often, which may have lowered their readings.\[1\] The authors call the trial an efficacy study and write that large-scale implementation would require broader inclusion criteria and cost-effective business models.\[1\]

Who was eligible is also a limit. Men had to be regular patrons, defined as at least one haircut every 6 weeks for at least 6 months, aged 35 to 79, with systolic pressure of 140 mm Hg or higher on two screening days.\[1\] The trial says nothing about men who do not frequent a barbershop. A 2020 review of barbershop research described the evidence as weak until this trial, and called for work on whether the model can be scaled and transferred to other regions and other at-risk groups.\[6\]

## The gap the trial was built to close

The trial was designed for a measured gap. In national survey data from 1999 to 2016, hypertension control was persistently lower for Black adults than for White adults of all ages, and awareness, treatment and control were higher among younger women than younger men.\[7\] A 2025 analysis of national survey data for adults aged 18 to 39 found that in 2021 to 2023 only 28.3% of young adults with hypertension were aware of it and 5.6% had pressure controlled to below 130/80 mm Hg. Disparities were greatest among young men and among non-Hispanic Black and Hispanic young adults, and a lack of a routine place for healthcare explained part of the age gap.\[8\]

These are national survey estimates with their own definitions, and they do not show why any one man's pressure is uncontrolled. Researchers who study barbershop patrons have also found that medical mistrust and everyday racism were associated with delays in blood pressure screening among Black men. That study was cross-sectional, drew on 610 men recruited mainly from barbershops between 2003 and 2009, and cannot show cause and effect.\[9\] Taken together, the studies describe a population with less routine contact with clinicians and a setting where the contact is already regular and trusted.

## The jobs inside the intervention

The back office of a clinical trial is easy to overlook, because the trial pays for it. The table below lists what the 2018 paper says it took, and a question for each item if the model were to run outside a study.\[1\]\[3\] The right-hand column is a prompt for reporting. It is not a description of how any health system works.

| **Job**                  | **How the trial handled it**                                                                                                                                  | **Open question outside a trial**                                     |
| ------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------- |
| Measuring pressure       | Barbers were trained, but checked pressure in only 6 of 28 intervention shops. Pharmacists took over measurement.\[1\]                                        | Who is accountable for accurate readings in a shop?                   |
| Prescribing              | Two doctoral-level pharmacists with specialty training and certification as hypertension clinicians prescribed under a collaborative practice agreement.\[1\] | Who employs such a pharmacist, and under what authority to prescribe? |
| Supervising doctor       | About 40% of participants had no doctor to sign the agreement, so a community physician served as supervisor.\[1\]                                            | Who is the supervising doctor for a man with no doctor?               |
| Lab monitoring           | Pharmacists checked electrolytes and creatinine at the shop with a point-of-care device after each medication change.\[1\]                                    | Who owns the equipment, the supplies and the result?                  |
| Medicine and travel cost | Intervention participants received $25 per pharmacist visit toward generic drugs and transportation.\[1\]                                                     | Who pays when the trial incentive ends?                               |
| Visits                   | On average, each man had seven in-person pharmacist visits and four pharmacist phone calls in six months, and contacted the pharmacist six times.\[1\]        | Who schedules and pays for this volume of contact?                    |
| Keeping men in           | Both groups received follow-up calls, culturally specific sessions and vouchers for monthly haircuts.\[1\]                                                    | Who funds the retention work after enrollment ends?                   |

One line in the paper's methods shows how much improvisation sat behind the results. Shops had far fewer eligible patrons than the team expected, so one barbershop owner, who is also an author, recruited about four times the planned number of shops. Among the 78 shops that completed six months, 26 enrolled zero or one participant and were dropped.\[1\]

## Why a result this size is not routine care

The most useful paper for this question is a cost-effectiveness analysis published in Circulation in 2021\. It used a computer simulation fed by the individual data from the trial. It is a projection, not a measurement of real spending. The first-year program cost was $3,713 per participant, and the largest part was pharmacist time at $2,623 per participant. The paper reports that 45.0% of that pharmacist time went to driving to barbershops and providing clinical care.\[3\]

Over 10 years, the simulation projected a cost of $2,356 more per participant than the comparison arm (the uncertainty interval, from −$264 to $4,611, includes zero) and a gain of 0.06 quality-adjusted life years. That worked out to $42,717 per quality-adjusted life year gained, which the authors classify as highly cost-effective under American College of Cardiology and American Heart Association thresholds. Using only generic drugs lowered the figure to $17,162\. The result was most sensitive to how often pharmacists intensified medicine at higher pressures and to pharmacist administrative and driving time. If a pharmacist managed each man in a barbershop for 10 years, the intervention was no longer cost-effective ($361,004 per quality-adjusted life year).\[3\]

Read together, these results explain the structure of the problem. The intervention costs more up front, the savings arrive later and mostly to someone else, and the most expensive input is a trained prescriber's time on the road. A shorter 26-week version was modeled at $18,300 per quality-adjusted life year, so the authors' scenarios suggest the design could be made leaner.\[3\] A proof-of-concept study from the same research group enrolled 10 men, 9 of whom finished, and switched to videoconference visits after blood pressure was controlled. The mean number of in-person visits fell from 11 in the main trial to 6.6, and 6 of 9 men (67%) reached control. The authors state that barriers to scaling include inefficiencies that raise cost, most notably pharmacist travel time.\[4\] Nine men cannot settle whether the leaner model works at scale.

None of the papers retrieved for this piece reports a health system or insurer adopting the model as routine, ongoing, paid care. That is a statement about the retrieved literature, not about every program in the country. It is the question MB would put to the systems themselves.

## What came after the trial

The follow-up work is still mostly research. A protocol published in 2023 describes the Community-to-Clinic Linkage Implementation Program, a cluster-randomized trial that adds trained community health workers to help barbershops adopt the model. It planned 20 barbershops and 420 men with elevated pressure or stage 1 hypertension, and it intends to evaluate sustainability and cost-effectiveness after the trial.\[11\] The 2025 baseline paper reports that the team enrolled 22 barbershops and 430 of 461 eligible men (93%), through 101 engagements with community partners and a partner community organization that did the recruiting.\[12\] The retrieved record contains the design and recruitment of this trial, but not its blood pressure results.

A feasibility study in a London borough worked with 8 barbers, trained online and in person, to take blood pressure readings. It captured 236 readings, of which 39 (16.5%) were above 140/90 mm Hg and 5 were above 180/100 mm Hg. The authors report that obtaining readings was difficult because customers worried about how their data would be recorded and because recording was impractical, and that barbers needed motivation, incentives and regular contact.\[10\] This is a small feasibility study, and it shows how much of the work lies in the barber's side of the exchange.

Barbershops have also been used for other purposes. In the MISTER B trial in New York City, 731 Black men aged 50 or older recruited at barbershops, all not up to date on colorectal screening and with uncontrolled blood pressure, were randomized to telephone navigation for screening, motivational interviewing for blood pressure, or both. At six months, 17.5% in the navigation group and 17.8% in the combined group had completed colorectal screening, versus 8.4% in the motivational interviewing group.\[13\] The finding fits the pattern in the blood pressure trial: the setting reached the men, and a person assigned to the next step moved the outcome. A 2024 review of barbershop interventions also lists training and resource provision for barbers, sustainability and scalability among the challenges still to be addressed.\[14\]

| **WHAT THE EVIDENCE CAN AND CANNOT TELL US** It can tell us that in one large Los Angeles trial, pharmacist-prescribed treatment delivered in barbershops lowered systolic pressure much more than barber education and doctor referral, and that the effect held at 12 months.\[1\]\[2\] It can tell us that the intervention depended on specific roles: trained prescribers, collaborative practice agreements, a supervising doctor for men without one, point-of-care lab checks and per-visit incentives.\[1\] It cannot tell us that the same result would occur in other cities, with men who do not visit barbershops, or when pharmacists work outside a research team. The authors call it an efficacy trial.\[1\] Its cost figures are simulated projections from trial data, not payments that anyone has made.\[3\] It cannot tell us why national control rates differ between groups. The survey studies describe gaps; they do not identify a single cause.\[7\]\[8\]\[9\] The retrieved record does not include results from the follow-up implementation trial or any report of routine paid adoption. |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |

| **QUESTIONS TO ASK IF A SHOP OR CLINIC OFFERS BLOOD PRESSURE CHECKS** If my reading is high, who is the next person who will see me, and when? Is there a clinician who can start or adjust medicine, or will I be told to find a doctor on my own? If I do not have a doctor, who will take responsibility for my follow-up? What will medicine and visits cost me, and who explains that before I commit? Who gets my reading, and how is the information stored and shared? These are questions to ask, not a diagnosis. A single reading does not establish hypertension; a clinician confirms it. |
| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |

## What MB will ask next

The trial answers whether the model can work. It leaves the operations question for others: who employs the pharmacist, who supervises the prescribing, who pays for the lab checks and the drive, and who is accountable when a man's pressure stays high after the first visit. MB will ask health systems, insurers and pharmacy regulators to say plainly whether any of them owns that chain today, and will report what they provide in writing.

General information, not individual medical advice. For emergencies, seek immediate help. The conversation continues.

## Sources (Peer-Reviewed Work Retrieved From Pubmed; Doi Links Included)

> \[1\] Victor RG, Lynch K, Li N, Blyler C, Muhammad E, Handler J, Brettler J, Rashid M, Hsu B, Foxx-Drew D, Moy N, Reid AE, Elashoff RM. A cluster-randomized trial of blood-pressure reduction in Black barbershops. N Engl J Med. 2018;378(14):1291-1301\. DOI: https://doi.org/10.1056/NEJMoa1717250 (PMID 29527973). Full text read via PMC6018053.  
>  
> \[2\] Victor RG, Blyler CA, Li N, Lynch K, Moy NB, Rashid M, Chang LC, Handler J, Brettler J, Rader F, Elashoff RM. Sustainability of blood pressure reduction in Black barbershops. Circulation. 2019;139(1):10-19\. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.038165 (PMID 30592662)  
>  
> \[3\] Bryant KB, Moran AE, Kazi DS, Zhang Y, Penko J, Ruiz-Negron N, Coxson P, Blyler CA, Lynch K, Cohen LP, Tajeu GS, Fontil V, Moy NB, Ebinger JE, Rader F, Bibbins-Domingo K, Bellows BK. Cost-effectiveness of hypertension treatment by pharmacists in Black barbershops. Circulation. 2021;143(24):2384-2394\. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.051683 (PMID 33855861). Full text read via PMC8206005.  
>  
> \[4\] Blyler CA, Ebinger J, Rashid M, Moy NP, Cheng S, Albert CM, Rader F. Improving efficiency of the barbershop model of hypertension care for Black men with virtual visits. J Am Heart Assoc. 2021;10(13):e020796\. DOI: https://doi.org/10.1161/JAHA.120.020796 (PMID 34155907)  
>  
> \[5\] Rader F, Elashoff RM, Niknezhad S, Victor RG. Differential treatment of hypertension by primary care providers and hypertension specialists in a barber-based intervention trial to control hypertension in Black men. Am J Cardiol. 2013;112(9):1421-1426\. DOI: https://doi.org/10.1016/j.amjcard.2013.07.004 (PMID 23978276)  
>  
> \[6\] Ebinger J, Blyler CA, Brettler J, Rader F. Barbershop management of hypertension in the African American population: pitfalls and opportunities for extension to other underserved communities. Curr Cardiol Rep. 2020;22(8):64\. DOI: https://doi.org/10.1007/s11886-020-01319-9 (PMID 32562103)  
>  
> \[7\] Foti K, Wang D, Appel LJ, Selvin E. Hypertension awareness, treatment, and control in US adults: trends in the hypertension control cascade by population subgroup (National Health and Nutrition Examination Survey, 1999-2016). Am J Epidemiol. 2019;188(12):2165-2174\. DOI: https://doi.org/10.1093/aje/kwz177 (PMID 31504121)  
>  
> \[8\] Tang R, An J, Bellows BK, Moran AE, Zhang Y. Trends in hypertension prevalence, awareness, treatment, and control among US young adults, 2003-2023\. Am J Hypertens. 2025;38(8):551-559\. DOI: https://doi.org/10.1093/ajh/hpaf044 (PMID 40156902)  
>  
> \[9\] Powell W, Richmond J, Mohottige D, Yen I, Joslyn A, Corbie-Smith G. Medical mistrust, racism, and delays in preventive health screening among African-American men. Behav Med. 2019;45(2):102-117\. DOI: https://doi.org/10.1080/08964289.2019.1585327 (PMID 31343960)  
>  
> \[10\] Thomas N, Ewart C, Lewinson Roberts D, Brown A. "You can change the world with a haircut": evaluating the feasibility of a barber-led intervention for men of Black and ethnic minority heritage to manage high blood pressure. J Prim Care Community Health. 2023;14:21501319231168336\. DOI: https://doi.org/10.1177/21501319231168336 (PMID 37148215)  
>  
> \[11\] Ravenell J, Green T, Arabadjian M, Schoenthaler A, Ogedegbe O. Barbershop-facilitated Community-to-Clinic Linkage Implementation Program: rationale and protocol for a novel program to prevent hypertension among Black men. Am J Hypertens. 2023;36(5):240-247\. DOI: https://doi.org/10.1093/ajh/hpac133 (PMID 37061797)  
>  
> \[12\] Arabadjian M, Green T, Foti K, Dubal M, Poudel B, Christenson A, Wang Z, Dietz K, Brown D, Liriano K, Onaga E, Mantello G, Schoenthaler A, Cooper LA, Spruill TM, Ogedegbe G, Ravenell J. Community engagement for effective recruitment of Black men at risk for hypertension: baseline data from the Community-to-Clinic Program (CLIP) randomized controlled trial. Am J Hypertens. 2025;38(11):888-895\. DOI: https://doi.org/10.1093/ajh/hpaf099 (PMID 40482027)  
>  
> \[13\] Cole H, Thompson HS, White M, Browne R, Trinh-Shevrin C, Braithwaite S, Fiscella K, Boutin-Foster C, Ravenell J. Community-based, preclinical patient navigation for colorectal cancer screening among older Black men recruited from barbershops: the MISTER B trial. Am J Public Health. 2017;107(9):1433-1440\. DOI: https://doi.org/10.2105/AJPH.2017.303885 (PMID 28727540)  
>  
> \[14\] Khosla P, Amin K, Doshi R. Combating chronic disease with barbershop health interventions: a review of current knowledge and potential for big data. Yale J Biol Med. 2024;97(2):239-245\. DOI: https://doi.org/10.59249/OTFP5065 (PMID 38947107)